NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of
Related Keywords
United States , Jeffrey Edwards , Christopheru Missling , Terrie Kellmeyer , Juan Carlos Lopez Talavera , Michael Houghton , Andrewj Barwicki , Clinical Development , Clinical Development At Acer Therapeutics , Facebook , Instagram , Regulatory Affairs , University Of Pittsburgh Medical Center , Amylin Pharmaceuticals , Michaelj Fox Foundation For Parkinson Research , Rochester Institute Of Technology , University Of Rochester , European Medicines Agency , Arena Pharmaceuticals , Madrigal Pharmaceuticals , James Madison University , Intercept Pharmaceuticals , Company On Twitter , Doctoral Fellowship At North Carolina State University , Linkedin , University Of Kentucky , Group Vice , Bristol Myers Squibb , Research Business Development , Head Of Research , Anavex Life Sciences Corp , Fractyl Health , Yale University , Life Sciences , Senior Vice President , Vice President , Clinical Pharmacology , Chief Executive Officer , Assistant Professor , Pittsburgh Medical Center , Nobel Prize , Sir Michael Houghton , Harvey Alter , Clinical Operations , Medical Affairs , New Drug Applications , Marketing Authorization Applications , Global Regulatory Affairs , Group Vice President , Rochester Institute , Molecular Biology , Post Doctoral Fellowship , Clinical Science , Acer Therapeutics , North Carolina State , Annual Report , Anavex Life Sciences , Further Information ,
vimarsana.com © 2020. All Rights Reserved.